FREEHOLD, N.J., June 10, 2019 /PRNewswire/ -- Avalon
GloboCare Corp. (NASDAQ: AVCO), a leading global developer of
cell-based technologies and therapeutics, today announced it has
achieved a major milestone in bio-production standardization of
clinical-grade stem cell derived exosomes. The standardized
procedure was a direct result of the previously announced
co-development program at Weill Cornell Medicine with
Yen-Michael Hsu, M.D., Ph.D. as
principal investigator. The process has been co-developed and
operated within Weill Cornell's cGMP-certified cell therapy
facility jointly accredited under Foundation of Accreditation for
Cellular Therapy (FACT), American Association of Blood Banking
(AABB), College of American Pathologists (CAP), as well as Clinical
Laboratory Improvement Amendment (CLIA).
Avalon will hold a press conference to announce the launch of
its exosome product commercialization plan, including a series of
over-the-counter skincare and wound-healing products with
Avalon's Clinical-grade Tissue-specific
EXosomes as additives (ACTEX), on June 15, 2019 during the 2nd
International Aesthetic Industry Conference in Chengdu, China -- the largest conference of
its kind in Asia. In addition to product commercialization,
this standardization of clinical-grade stem cell derived exosomes
will lead to parallel development of Avalon's clinical programs,
including AVA-202 and AVA-203, for angiogenic/orthopedic
regeneration as well as treatment of fibrotic diseases.
"We are pleased to complete such a significant developmental
milestone of our exosome program," stated David Jin, M.D., Ph.D., CEO and President of
Avalon GloboCare and Co-CEO of its subsidiary GenExosome
Technologies. "As a result, we look forward to an accelerated
pathway of our exosome-based clinical programs for regenerative
therapeutics as well as exosome product commercialization," added
Dr. Jin.
About Avalon GloboCare Corp.
Avalon GloboCare Corp. (NASDAQ: AVCO) is a leading CellTech
bio-developer dedicated to advancing and empowering innovative,
transformative exosome technologies and cellular therapeutics.
Avalon also provides strategic advisory and outsourcing services to
facilitate and enhance its clients' growth, development, as well as
competitiveness in both the domestic and global healthcare markets.
Through its subsidiaries, namely GenExosome Technologies Inc. and
Avactis Biosciences Inc., Avalon is establishing a leading role in
the fields of exosome-based diagnostics (''liquid biopsy''),
cellular immunotherapy (including CAR-T/CAR-NK), and regenerative
medicine.
Forward-Looking Statements
Certain statements contained in this press release may
constitute "forward-looking statements." Forward-looking
statements provide current expectations of future events based on
certain assumptions and include any statement that does not
directly relate to any historical or current fact. Actual results
may differ materially from those indicated by such forward-looking
statements as a result of various important factors as disclosed in
our filings with the Securities and Exchange Commission located at
their website (http://www.sec.gov). In addition to
these factors, actual future performance, outcomes, and results may
differ materially because of more general factors including
(without limitation) general industry and market conditions and
growth rates, economic conditions, and governmental and public
policy changes. The forward-looking statements included in this
press release represent the Company's views as of the date of this
press release and these views could change. However, while the
Company may elect to update these forward-looking statements at
some point in the future, the Company specifically disclaims any
obligation to do so. These forward-looking statements should not be
relied upon as representing the Company's views as of any date
subsequent to the date of the press release.
View original
content:http://www.prnewswire.com/news-releases/avalon-globocare-announces-completion-of-clinical-grade-exosome-bio-production-standardization-with-launch-of-actex-product-commercialization-300864290.html
SOURCE Avalon GloboCare Corp.